BETHANY VROUHAS: Open Payments
NPI 1417403650 · CHELMSFORD, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$775 in 25 payments from 13 companies in 2025. Trend: 2023 $354 · 2024 $315 · 2025 $775
Food & beverage: $775
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 4 | $160 |
| Novo Nordisk Inc | 3 | $138 |
| ACADIA Pharmaceuticals Inc | 1 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $84 |
| Exact Sciences Corporation | 3 | $62 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $47 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
| GlaxoSmithKline, LLC. | 1 | $28 |
| E.R. Squibb & Sons, L.L.C. | 1 | $27 |
| Indivior Inc. | 1 | $26 |
Products named: KISUNLA, Ozempic, NUPLAZID, REXULTI, The Cologuard Plus Collection Kit, JARDIANCE, TRELEGY ELLIPTA, ELIQUIS.
Industry payments across MA — which companies pay providers there.
